These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28358435)

  • 21. Prognostic Impact of Immune-Related Gene Expression in Preoperative Peripheral Blood from Gastric Cancer Patients.
    Ito S; Fukagawa T; Noda M; Hu Q; Nambara S; Shimizu D; Kuroda Y; Eguchi H; Masuda T; Sato T; Katai H; Sasako M; Mimori K
    Ann Surg Oncol; 2018 Nov; 25(12):3755-3763. PubMed ID: 30203407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterogeneous expansion of CD4+ tumor-infiltrating T-lymphocytes in clear cell renal cell carcinomas.
    Zhang Q; Jia Q; Deng T; Song B; Li L
    Biochem Biophys Res Commun; 2015 Feb; 458(1):70-6. PubMed ID: 25637538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy.
    Lim YJ; Koh J; Kim K; Chie EK; Kim B; Lee KB; Jang JY; Kim SW; Oh DY; Bang YJ; Ha SW
    Radiother Oncol; 2015 Oct; 117(1):165-70. PubMed ID: 26235847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal Cell Carcinoma (RCC) Tumors Display Large Expansion of Double Positive (DP) CD4+CD8+ T Cells With Expression of Exhaustion Markers.
    Menard LC; Fischer P; Kakrecha B; Linsley PS; Wambre E; Liu MC; Rust BJ; Lee D; Penhallow B; Manjarrez Orduno N; Nadler SG
    Front Immunol; 2018; 9():2728. PubMed ID: 30534127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD11c-Positive Dendritic Cells in Triple-negative Breast Cancer.
    Lee H; Lee HJ; Song IH; Bang WS; Heo SH; Gong G; Park IA
    In Vivo; 2018; 32(6):1561-1569. PubMed ID: 30348717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
    Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
    Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Significance of the Immune Microenvironment in Endometrial Cancer.
    Lee M; Jung W; Kang J; Lee KH; Lee SJ; Hong SH; Kang J; Lee A
    Lab Invest; 2024 Sep; 104(9):102126. PubMed ID: 39174007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis.
    Brunner A; Hinterholzer S; Riss P; Heinze G; Brustmann H
    Gynecol Oncol; 2012 Jan; 124(1):105-11. PubMed ID: 21982044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunofluorescence-detected infiltration of CD4+FOXP3+ regulatory T cells is relevant to the prognosis of patients with endometrial cancer.
    Yamagami W; Susumu N; Tanaka H; Hirasawa A; Banno K; Suzuki N; Tsuda H; Tsukazaki K; Aoki D
    Int J Gynecol Cancer; 2011 Dec; 21(9):1628-34. PubMed ID: 21897268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clonal Expansion of Tumor-Infiltrating T Cells and Analysis of the Tumor Microenvironment within Esophageal Squamous Cell Carcinoma Relapsed after Definitive Chemoradiation Therapy.
    Mori T; Kumagai K; Nasu K; Yoshizawa T; Kuwano K; Hamada Y; Kanazawa H; Suzuki R
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
    Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intratumoral expression levels of
    Inoue H; Park JH; Kiyotani K; Zewde M; Miyashita A; Jinnin M; Kiniwa Y; Okuyama R; Tanaka R; Fujisawa Y; Kato H; Morita A; Asai J; Katoh N; Yokota K; Akiyama M; Ihn H; Fukushima S; Nakamura Y
    Oncoimmunology; 2016; 5(9):e1204507. PubMed ID: 27757299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
    Chen S; Wang RX; Liu Y; Yang WT; Shao ZM
    Int J Cancer; 2017 Mar; 140(6):1384-1395. PubMed ID: 27925176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of microRNA-200c expression levels with clinicopathological factors and prognosis in endometrioid endometrial cancer.
    Wilczynski M; Danielska J; Domanska-Senderowska D; Dzieniecka M; Szymanska B; Malinowski A
    Acta Obstet Gynecol Scand; 2018 May; 97(5):560-569. PubMed ID: 29355888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma.
    Keane C; Gould C; Jones K; Hamm D; Talaulikar D; Ellis J; Vari F; Birch S; Han E; Wood P; Le-Cao KA; Green MR; Crooks P; Jain S; Tobin J; Steptoe RJ; Gandhi MK
    Clin Cancer Res; 2017 Apr; 23(7):1820-1828. PubMed ID: 27649554
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
    Pelekanou V; Carvajal-Hausdorf DE; Altan M; Wasserman B; Carvajal-Hausdorf C; Wimberly H; Brown J; Lannin D; Pusztai L; Rimm DL
    Breast Cancer Res; 2017 Aug; 19(1):91. PubMed ID: 28784153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of HLA class I and mismatch repair protein expression in sporadic endometrioid endometrial carcinomas.
    de Jong RA; Boerma A; Boezen HM; Mourits MJ; Hollema H; Nijman HW
    Int J Cancer; 2012 Oct; 131(8):1828-36. PubMed ID: 22287095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.
    Schalper KA; Velcheti V; Carvajal D; Wimberly H; Brown J; Pusztai L; Rimm DL
    Clin Cancer Res; 2014 May; 20(10):2773-82. PubMed ID: 24647569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T cell receptor β-chain repertoire analysis reveals intratumour heterogeneity of tumour-infiltrating lymphocytes in oesophageal squamous cell carcinoma.
    Chen Z; Zhang C; Pan Y; Xu R; Xu C; Chen Z; Lu Z; Ke Y
    J Pathol; 2016 Aug; 239(4):450-8. PubMed ID: 27171315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.